Instylla is a series b startup. 1 investor tracked. Status: possibledead.
Instylla is a startup founded in 2019 based in the United States. Its most recent tracked round is Series B. Brouky records 2 investors associated with the company.
Instylla develops next-generation liquid embolic agents for interventional radiology, focusing on applications in interventional oncology and peripheral hemostasis. Their products, such as the Embrace Hydrogel Embolic System and the Tembo Embolic System, are designed to provide precise and controlled embolization for treating hypervascular tumors and managing vascular bleeds.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.